Innovative Infection Control Prescient Surgical's flagship product, CleanCision™, offers a unique active cleansing technology designed to reduce surgical site infections, making it highly appealing to hospitals seeking advanced infection prevention solutions.

Strong Clinical Recognition The company's recognition as a finalist in the 2018 Medical Design Excellence Awards validates its innovative approach, positioning it as a credible partner for healthcare providers focused on cutting-edge surgical technologies.

Strategic Partnerships Recent signing of a group purchasing agreement with Premier indicates growing adoption and interest from hospital networks, providing a pathway for expanding sales opportunities within major healthcare systems.

Funding and Growth Potential Although current revenue is modest, the $10M Series B funding round led by Baxter Ventures suggests strong investor confidence, enabling Prescient Surgical to scale its sales efforts and expand market reach.

Collaborative Development Partnerships with organizations like UserWise for human factors testing demonstrate a commitment to usability and safety, which can be leveraged to build trust and facilitate adoption among clinicians and surgical teams.